Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

Correspondence on Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”

Joo Hyun Oh, Dong Hyun Sinn

Clin Mol Hepatol. 2023;29(3):820-820. Published online May 19, 2023

DOI: https://doi.org/10.3350/cmh.2023.0135

View: 1544 Download: 27

Original Article

Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients

Xiaoning Wu, Xiaoqian Xu, Jialing Zhou, Yameng Sun, Huiguo Ding, Wen Xie, Guofeng Chen, Anlin Ma, HongXin Piao, Bingqiong Wang, Shuyan Chen, Tongtong Meng, Xiaojuan Ou, Hwai-I Yang, Jidong Jia, Yuanyuan Kong, Hong You

Clin Mol Hepatol. 2023;29(3):747-762. Published online May 10, 2023

DOI: https://doi.org/10.3350/cmh.2023.0121

View: 2301 Download: 128

Editorial

Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?

Joo Hyun Oh, Dong Hyun Sinn

Clin Mol Hepatol. 2023;29(2):367-370. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0054 Correction in: Clin Mol Hepatol 2023;29(3):828

View: 2308 Download: 62 Web of Science: 3 Crossref: 2

Original Article

Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B

Lilian Yan Liang, Hye Won Lee, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip, Yee-Kit Tse, Vicki Wing-Ki Hui, Grace Chung-Yan Lui, Henry Lik-Yuen Chan, Grace Lai-Hung Wong

Clin Mol Hepatol. 2021;27(3):499-509. Published online February 26, 2021

DOI: https://doi.org/10.3350/cmh.2020.0333

View: 4469 Download: 134 Web of Science: 14 Crossref: 14

Editorial

Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status?

Ho Soo Chun, Minjong Lee

Clin Mol Hepatol. 2021;27(3):448-450. Published online June 23, 2021

DOI: https://doi.org/10.3350/cmh.2021.0130

View: 3743 Download: 119 Web of Science: 1 Crossref: 1

Original Article

Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial

Do Seon Song, Won Kim, Sang Hoon Ahn, Hyung Joon Yim, Jae Young Jang, Young Oh Kweon, Yong Kyun Cho, Yoon Jun Kim, Gun Young Hong, Dong Joon Kim, Young Kul Jung, Joo Hyun Sohn, Jin-Woo Lee, Sung Jae Park, Byung Seok Lee, Ju Hyun Kim, Hong Soo Kim, Seung Kew Yoon, Moon Young Kim, Kwan Sik Lee, Young Suk Lim, Wan Sik Lee, Jin Mo Yang, Kyun-Hwan Kim, Kwang-Hyub Han, Soon Ho Um

Clin Mol Hepatol. 2021;27(2):346-359. Published online January 25, 2021

DOI: https://doi.org/10.3350/cmh.2020.0307

View: 5464 Download: 236 Web of Science: 11 Crossref: 9

Editorial

Another oral antiviral treatment, but still far away from hepatitis B virus cure

Tai-Chung Tseng

Clin Mol Hepatol. 2021;27(2):281-282. Published online March 10, 2021

DOI: https://doi.org/10.3350/cmh.2021.0072

View: 3523 Download: 99 Web of Science: 5 Crossref: 5

Review

Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop

Hyung Joon Yim, Ji Hoon Kim, Jun Yong Park, Eileen L. Yoon, Hana Park, Jung Hyun Kwon, Dong Hyun Sinn, Sae Hwan Lee, Jeong-Hoon Lee, Hyun Woong Lee

Clin Mol Hepatol. 2020;26(4):411-429. Published online August 28, 2020

DOI: https://doi.org/10.3350/cmh.2020.0049

View: 14410 Download: 1,426 Web of Science: 63 Crossref: 64

Original Article

Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017

Seung Ha Park, Lindsay D. Plank, Ki Tae Suk, Yong Eun Park, Jin Lee, Joon Hyuk Choi, Nae Yun Heo, Jongha Park, Tae Oh Kim, Young Soo Moon, Hyun Kuk Kim, Hang Jea Jang, Ha Young Park, Dong Joon Kim

Clin Mol Hepatol. 2020;26(2):209-215. Published online November 4, 2019

DOI: https://doi.org/10.3350/cmh.2019.0065

View: 33753 Download: 402 Web of Science: 76 Crossref: 79

Review

The fibrogenic process and the unleashing of acute-on-chronic liver failure

Guillermo Nahúm López-Sánchez, Mayra Dóminguez-Pérez, Misael Uribe, Natalia Nuño-Lámbarri

Clin Mol Hepatol. 2020;26(1):7-15. Published online June 14, 2019

DOI: https://doi.org/10.3350/cmh.2019.0011

View: 11271 Download: 365 Web of Science: 9 Crossref: 10

Original Article

Hepatitis B screening rates and reactivation in solid organ malignancy patients undergoing chemotherapy in Southern Thailand

Ratchapong Laiwatthanapaisan, Pimsiri Sripongpun, Naichaya Chamroonkul, Arunee Dechaphunkul, Chirawadee Sathitruangsak, Siwat Sakdejayont, Chanon Kongkamol, Teerha Piratvisuth

Clin Mol Hepatol. 2019;25(4):366-373. Published online July 17, 2019

DOI: https://doi.org/10.3350/cmh.2018.0111

View: 5102 Download: 107 Web of Science: 3 Crossref: 5

Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir

David Sooik Kim, Mi Young Jeon, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim

Clin Mol Hepatol. 2019;25(3):283-293. Published online November 13, 2018

DOI: https://doi.org/10.3350/cmh.2018.0054

View: 9905 Download: 240 Web of Science: 29 Crossref: 33

Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B

Jeong Han Kim, Hee Won Moon, Soon Young Ko, Won Hyeok Choe, So Young Kwon

Clin Mol Hepatol. 2014;20(3):274-282. Published online September 25, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.3.274

View: 6622 Download: 43 Web of Science: 3 Crossref: 2

2

Genetic epidemiological study on single nucleotide polymorphisms associated with hepatocellular carcinoma in patients with chronic HBV infection

Yoon Jun Kim , Hyo Suk Lee

Clin Mol Hepatol. 2009;15(1):7-14. Published online March 31, 2009

DOI: https://doi.org/10.3350/kjhep.2009.15.1.7

View: 5345 Download: 40 Crossref: 3

4

A case report of treatment with pegylated interferon alpha for Lamivudine-resistant chronic hepatitis B virus infection

Won Haing Hur , Hyun Young Woo , Soung Won Jeong , Chan Ran You , Si Hyun Bae , Jong Young Choi , Seung Kew Yoon

Clin Mol Hepatol. 2008;14(4):513-518. Published online December 31, 2008

DOI: https://doi.org/10.3350/kjhep.2008.14.4.513

View: 4623 Download: 30 Crossref: 1

7

The Korean Journal of Entecavir 1 mg therapy for Lamivudine-refractory chronic hepatitis B

Hyung Joon Kim

Clin Mol Hepatol. 2008;14(3):411-416. Published online September 30, 2008

DOI: https://doi.org/10.3350/kjhep.2008.14.3.411

View: 3873 Download: 15

The Korean Journal of Adefovir plus Lamivudine combination therapy in Lamivudine-resistant chronic hepatitis B

So Young Kwon

Clin Mol Hepatol. 2008;14(2):235-239. Published online June 20, 2008

DOI: https://doi.org/10.3350/kjhep.2008.14.2.235

View: 3561 Download: 15

The Korean Journal of Normal range of serum ALT level in patients with chronic hepatitis

Yeon Seok Seo

Clin Mol Hepatol. 2008;14(1):116-121. Published online March 20, 2008

DOI: https://doi.org/10.3350/kjhep.2008.14.1.116

View: 4127 Download: 18

3

Change of HBV DNA Level as a Predictor of HBeAg Loss after Lamivudine Treatment

Jae Kwon Jung, M.D., Chang Hyeong Lee, M.D., Eun Young Kim, M.D., Jin Tae Jung, M.D., Joon Hyuck Choi, M.D., Ji Min Han, M.D., Myoung In Jin, M.D., Ju Yeon Cho, M.D., Byung Seok Kim, M.D., Im Hee Shin, Ph.D.

Clin Mol Hepatol. 2007;13(4):513-520. Published online December 20, 2007

DOI: https://doi.org/10.3350/kjhep.2007.13.4.513

View: 3624 Download: 28

The Efficacy and Safety of Telbivudine in Korean Patients with Chronic Hepatitis B

Young-Myoung Moon, M.D. Seong-Gyu Hwang, M.D. Boo-Sung Kim, M.D. Kyu-Sung Rim, M.D. Mong Cho, M.D. Dong-Joon Kim, M.D. Joon-Yeol Han, M.D. Young-Seok Kim, M.D. Ho-Soon Choi, M.D. Sang-Hoon Ahn, M.D.

Clin Mol Hepatol. 2007;13(4):503-512. Published online December 20, 2007

DOI: https://doi.org/10.3350/kjhep.2007.13.4.503

View: 4469 Download: 29 Crossref: 6

Effect of Initial Virologic Response to Adefovir on the Development of Resistance to Adefovir in Lamivudine-resistant Chronic Hepatitis B

In Hee Kim , Seong Hun Kim , Hyun Chul Kim , Kyoung Deok Shin , Sang Wook Kim , Seong Ok Lee , Soo Teik Lee , Dae Ghon Kim

Clin Mol Hepatol. 2007;13(3):349-362. Published online September 20, 2007

DOI: https://doi.org/10.3350/kjhep.2007.13.3.349

View: 3988 Download: 18 Crossref: 1

Predictors of Lamivudine Resistance in Patients with Chronic Hepatitis B Virus Infection

Jeong Heo , Mong Cho , Byung Mann Cho , Sun Mi Lee , Tae Oh Kim , Gwang Ha Kim , Dae Hwan Kang , Geun Am Song

Clin Mol Hepatol. 2007;13(2):157-165. Published online January 1, 1970

View: 2713 Download: 15

Clinical Outcomes of Lamivudine Therapy in HBeAg Positive Chronic Hepatitis B with Minimally Elevated ALT

Dong Ha Han , Neung Hwa Park , Jung Woo Shin , Seok Won Jung , Young Tae Hwang , Hyun Soo Kim , In Du Jeong , Sung Jo Bang , Do Ha Kim

Clin Mol Hepatol. 2007;13(2):146-156. Published online January 1, 1970

View: 2711 Download: 20

Clinical Significances of Serum Soluble Fas and Soluble Fas Ligand in Chronic Hepatitis B

Eun Jung Jun, M.D., Joon-Yeol Han, M.D., and Hee Sik Sun, M.D.

Clin Mol Hepatol. 2006;12(4):507-514. Published online January 1, 1970

View: 2683 Download: 21

2

Resistance to Adefovir in Patients with Chronic Hepatitis B

Soo Hyung Ryu, M.D.,* Young-Hwa Chung, M.D.

Clin Mol Hepatol. 2006;12(4):484-492. Published online January 1, 2000

View: 2723 Download: 27

3

Comparison of Clinical Outcome Between Patients Continuing and Discontinuing Lamivudine Therapy in Acute Exacerbation After Viral breakthrough During Lamivudine Therapy in Chronic Hepatitis B

Jong Ryul Eun

Clin Mol Hepatol. 2006;12(2):184-190. Published online January 1, 1970

View: 2090 Download: 14

Correlation of HBV DNA Level and Viral Breakthrough During Lamivudine Therapy for Chronic Hepatitis B

Hee Seung Park , Dong Hyun Lee , Jeong Heo , Gwang Ha Kim , Dae Hwan Kang , Geun Am Song , Mong Cho

Clin Mol Hepatol. 2006;12(2):173-183. Published online January 1, 1970

View: 2706 Download: 22

Natural History of HBeAg Negative Chronic Hepatitis B Virus Infection; A Cohort Study

Chang Mo Moon, M.D., Do Young Kim, M.D., Ki Jun Song, Ph.D. Ja Kyung Kim, M.D., Hyun Woong Lee, M.D., Jung Min Lee, M.D., Ki Tae Yoon, M.D., Yong Han Paik, M.D., Dong Ki Kim, Ph.D. Kwang-Hyub Han, M.D., Chae Yoon Chon, M.D., Young Myoung Moon, M.D., and Sang Hoon Ahn, M.D.

Clin Mol Hepatol. 2006;12(2):163-172. Published online January 1, 1970

View: 2272 Download: 27

2

Action Mechanism in Immunopathogenesis and Clearance of HBV

Se Jin Im , Young Chul Sung

Clin Mol Hepatol. 2006;12(2):154-162. Published online January 1, 1970

View: 2723 Download: 47

1

Clinical Significance and Natural History of "HBeAg Negativity" in Patients with Chronic HBV Infection

Young Sok Lee

Clin Mol Hepatol. 2006;12(2):133-135. Published online January 1, 1970

View: 2418 Download: 18

1 |

Viewed By 5282	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5222	MAFLD: How is it different from NAFLD?
Viewed By 5124	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3841	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3778	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 52	MAFLD: How is it different from NAFLD?

Search